Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Using data from the Canadian Hemophilia Bleeding Disorders Registry, this study describes the demographics of people with hemophilia A receiving emicizumab prophylaxis and assesses the effectiveness and safety of this therapy as well as looking at treatment patterns and impact on disease burden.

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Using data from the Canadian Hemophilia Bleeding Disorders Registry, this study describes the demographics of people with hemophilia A receiving emicizumab prophylaxis and assesses the effectiveness and safety of this therapy as well as looking at treatment patterns and impact on disease burden.

{{assetTitle}}

Welcome to Medically

The Roche Science Hub

You are Leaving Medically

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Using data from the Canadian Hemophilia Bleeding Disorders Registry, this study describes the demographics of people with hemophilia A receiving emicizumab prophylaxis and assesses the effectiveness and safety of this therapy as well as looking at treatment patterns and impact on disease burden.

{{assetTitle}}

Related content

Welcome to Medically

The Roche Science Hub

You are Leaving Medically

You need to have cookies enabled to save content